Atlas Trials

Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)

Clinical trial NCT05071222 · RECRUITING

Trial details

NCT number
NCT05071222
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency
Start date
2023-07-19
Primary completion
2041-11-19
Enrollment
7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.